2-(2-Bromophenyl)-2,3-dihydro-1h-naphtho[1,8-de][1,3,2]diazaborine

Catalog No. :
ACXDZH230
CAS No. :
927384-42-7
Molecular Formula :
C16H12BBrN2
Molecular Weight :
323.00

IUPAC Name:2-(2-bromophenyl)-2,3-dihydro-1H-naphtho[1,8-de][1,3,2]diazaborinine

2-(2-Bromophenyl)-2,3-dihydro-1h-naphtho[1,8-de][1,3,2]diazaborine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$78.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(2-Bromophenyl)-2,3-dihydro-1h-naphtho[1,8-de][1,3,2]diazaborine
IUPAC Name2-(2-bromophenyl)-2,3-dihydro-1H-naphtho[1,8-de][1,3,2]diazaborinine
MDL No.MFCD16038144
Molecular FormulaC16H12BBrN2
Molecular Weight323.00
SMILESBrC1=CC=CC=C1B2NC3=CC=CC4=C3C(N2)=CC=C4
InChI KeyVHWWJBPYVUEFBM-UHFFFAOYSA-N
SynonymAKOS015835207 | MFCD16038144 | CMB38442 | CS-0156725 | 2-Bromo-1-(2,3-dihydro-1H-naphtho[1,8-de]-1,3,2-diazaborinyl)benzene | B3653 | BS-44520 | 2-(2-Bromophenyl)-2,3-dihydro-1H-naphtho[1,8-de][1,3,2]diazaborinine | 2-(2-Bromophenyl)-2,3-dihydro-1H-naphth
CAS No.927384-42-7
PubChem CID53384411

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACXDZH230 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRMJN620 route compound structure diagram
    ACRMJN6202973762-38-6 In Stock
  2. Plus
  3. ACJTYB425 route compound structure diagram
    ACJTYB425244205-40-1 In Stock
  4. Then
  5. ACXDZH230 route product structure diagram
    ACXDZH230927384-42-7 In Stock
Inquiry

2. ACXDZH230 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACXDZH230 route product structure diagram
    ACXDZH230927384-42-7 In Stock
Inquiry

Comments (0)